1. Search Result
Search Result
Results for "

M5

" in MedChemExpress (MCE) Product Catalog:

72

Inhibitors & Agonists

2

Fluorescent Dye

9

Biochemical Assay Reagents

1

Peptides

3

Inhibitory Antibodies

2

Natural
Products

9

Isotope-Labeled Compounds

1

Antibodies

1

Click Chemistry

6

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132578

    Phosphatase Cancer
    M5N36 is a potent and selective Cdc25C inhibitor with IC50 values of 0.15, 0.19, 0.06 µM for Cdc25A, Cdc25B, Cdc25C, respectively. M5N36 shows anti-proliferative activity and increases the expression of p-CDK1 and p-CDK2 .
    M5N36
  • HY-N7922

    Decarboxyellagic acid

    Influenza Virus Infection
    Urolithin M5 is a neuraminidase inhibitor that can be isolated from Ganlanye. Urolithin M5 has antiviral activity in vitro and in vivo by inhibiting the activity of viral NA. Urolithin M5 can increase the survival rate and improve pulmonary edema in pr8-infected mouse models. Urolithin M5 can be used in anti-influenza research .
    Urolithin M5
  • HY-158485

    Mannose-5 N-linked oligosaccharide; Oligomannose 5 glycan

    Biochemical Assay Reagents Others
    M5 glycan (Man5) (Mannose-5 N-linked oligosaccharide; Oligomannose 5 glycan) is a N-polysaccharide protein and a multifunctional fluorescent linker. The resulting conjugates exhibit high sensitivity and specificity by mimicking the antennal elements of N-glycans .
    M5 glycan (Man5)
  • HY-158505

    Mannose-5 N-linked oligosaccharide, APTS labelled; Oligomannose 5 glycan, APTS labelled

    Biochemical Assay Reagents Others
    M5 glycan (Man5), APTS labelled (Mannose-5 N-linked oligosaccharide, APTS labelled; Oligomannose 5 glycan, APTS labelled) is a N-polysaccharide protein and a multifunctional fluorescent linker. The resulting conjugates exhibit high sensitivity and specificity by mimicking the antennal elements of N-glycans .
    M5 glycan (Man5), APTS labelled
  • HY-158507

    Mannose-5 N-linked oligosaccharide, procainamide labelled; Oligomannose 5 glycan, procainamide labelled

    Biochemical Assay Reagents Others
    M5 glycan (Man5), procainamide labelled (Mannose-5 N-linked oligosaccharide, procainamide labelled; Oligomannose 5 glycan, procainamide labelled) is a N-polysaccharide protein and a multifunctional fluorescent linker. The resulting conjugates exhibit high sensitivity and specificity by mimicking the antennal elements of N-glycans .
    M5 glycan (Man5), procainamide labelled
  • HY-158503

    Mannose-5 N-linked oligosaccharide, 2-AB labelled; Oligomannose 5 glycan, 2-AB labelled

    Biochemical Assay Reagents Others
    M5 glycan (Man5), 2-AB labelled (Mannose-5 N-linked oligosaccharide, 2-AB labelled; Oligomannose 5 glycan, 2-AB labelled) is a N-polysaccharide protein and a multifunctional fluorescent linker. The resulting conjugates exhibit high sensitivity and specificity by mimicking the antennal elements of N-glycans .
    M5 glycan (Man5), 2-AB labelled
  • HY-158501

    Mannose-5 N-linked oligosaccharide, 2-AA labelled; Oligomannose 5 glycan, 2-AA labelled

    Biochemical Assay Reagents Others
    M5 glycan (Man5), 2-AA labelled (Mannose-5 N-linked oligosaccharide, 2-AA labelled; Oligomannose 5 glycan, 2-AA labelled) is a N-polysaccharide protein and a multifunctional fluorescent linker. The resulting conjugates exhibit high sensitivity and specificity by mimicking the antennal elements of N-glycans .
    M5 glycan (Man5), 2-AA labelled
  • HY-136997

    Drug Derivative Others
    M-5MPEP is an active compound.
    M-5MPEP
  • HY-108226

    N-Desmethyl regorafenib N-oxide

    Drug Metabolite Raf VEGFR c-Kit Cancer
    Regorafenib N-oxide and N-desmethyl (M5) (N-Desmethyl regorafenib N-oxide) is an active metabolite of Sorafenib (HY-10201) and can be metabolized by CYP3A4 .
    Regorafenib N-oxide and N-desmethyl (M5)
  • HY-P10875

    Hedgehog Cancer
    HL2-m5 is the inhibitor for the interaction between sonic hedgehog/patched (Shh/PTCH1) with Kd of 170 nM for Shh. HL2-m5 inhibits activation of Hedgehog signaling pathway and transcription of Gli-controlled gene with an IC50 of 230 nM .
    HL2-m5
  • HY-12439
    ML380
    1 Publications Verification

    mAChR Neurological Disease
    ML380 is a potent, subtype-selective, and brain-penetrant positive allosteric modulator (PAM) of M5 mAChR, with EC50s of 190 and 610 nM for human and rat M5, respectively. ML380 exhibits moderate selectivity versus the M1 and M3 mAChR subtypes. ML380 could increase the affinity of ACh for the M5 mAChR .
    ML380
  • HY-108226S1

    Isotope-Labeled Compounds Others
    Regorafenib N-oxide and N-desmethyl (M5)- 13C6 is the 13C-labeled Regorafenib N-oxide and N-desmethyl (M5)[1].
    Regorafenib N-oxide and N-desmethyl (M5)-13C6
  • HY-108226S

    N-Desmethyl regorafenib N-oxide-d3

    Isotope-Labeled Compounds Others
    Regorafenib N-oxide and N-desmethyl (M5)-d3 is deuterium labeled Regorafenib N-oxide and N-desmethyl (M5).
    Regorafenib N-oxide and N-desmethyl (M5)-d3
  • HY-12567

    VU0483253

    mAChR Neurological Disease
    ML375 (VU0483253) is a potent, highly selective, brain-penetrant and orally active M5 mAChR negative allosteric modulator (NAM) with IC50s of 300 nM and 790 nM for human and rat M5, respectively. ML375 is inactive at human and rat M1-M4 .
    ML375
  • HY-101281

    mAChR Neurological Disease
    VU 6008667 is a selective negative allosteric modulator of M5 NAM with IC50s of 1.2 μM and 1.6 μM for human M5 and rat M5, respectively. High CNS penetration .
    VU 6008667
  • HY-114933

    mAChR Metabolic Disease
    VU0119498 is a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM), with EC50s of 6.04, 6.38, and 4.08 µM, respectively. VU0119498 has antidiabetic activity .
    VU0119498
  • HY-159578S

    mAChR Neurological Disease
    VU6036864 (compound 45) is an orally active, selective mAChR M5 antagonist with IC50=20 nM for human M5. VU6036864 is >500-fold selective for human M1-4, with BBB characteristic and high oral bioavailability (%F>100%) .
    VU6036864
  • HY-12100
    Umeclidinium bromide
    1 Publications Verification

    GSK573719A

    mAChR Inflammation/Immunology Cancer
    Umeclidinium bromide is a novel mAChR antagonist. The affinity (Ki) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.
    Umeclidinium bromide
  • HY-12157
    VU 0238429
    1 Publications Verification

    mAChR Others
    VU 0238429 is positive allosteric modulator of muscarinic acetylcholine receptor subtype 5 (mAChR5 or M5), with an EC50 of 1.16 μM.
    VU 0238429
  • HY-A0030

    mAChR Neurological Disease Metabolic Disease Cancer
    Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB) .
    Fesoterodine fumarate
  • HY-70053

    mAChR Neurological Disease Metabolic Disease
    Fesoterodine is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine is used for the overactive bladder (OAB) .
    Fesoterodine
  • HY-101281B

    mAChR Neurological Disease
    (R)-VU 6008667, the less active (R)-enantiomer to VU 6008667, is devoid of M5 NAM activity (IC50>10 μM) .
    (R)-VU 6008667
  • HY-148502
    VU6019650
    1 Publications Verification

    mAChR Neurological Disease
    VU6019650 is a potent and selective orthosteric antagonist of M5 mAChR (IC50=36 nM), can be used for opioid use disorder (OUD) relief. VU6019650 can cross blood brain barrier, potentially modulates the mesolimbic dopaminergic reward circuitry. VU6019650 blocks Oxotremorine M iodide (HY-101372A) induced increases of neuronal firing rates of midbrain dopamine neurons in the ventral tegmental area (VTA) .
    VU6019650
  • HY-70053A

    mAChR Neurological Disease Metabolic Disease Cancer
    Fesoterodine L-mandelate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine L-mandelate is used for the overactive bladder (OAB) .
    Fesoterodine L-mandelate
  • HY-155367

    mAChR Neurological Disease
    mAChR antagonist 1 (compound 4a) is a mAChR antagonist with Ki values of 255 nM, 121 nM, 158 nM, and 255 nM for M1, M3, M4, and M5 subtype, respectively .
    mAChR antagonist 1
  • HY-12100S

    GSK573719A-d5

    Isotope-Labeled Compounds mAChR Inflammation/Immunology
    Umeclidinium-d5 (bromide) is the deuterium labeled Umeclidinium bromide. Umeclidinium bromide is a novel mAChR antagonist. The affinity (Ki) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.
    Umeclidinium-d5 bromide
  • HY-12100S1

    GSK573719A-d10

    mAChR Inflammation/Immunology
    Umeclidinium-d10 (bromide) is the deuterium labeled Umeclidinium bromide. Umeclidinium bromide is a novel mAChR antagonist. The affinity (Ki) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.
    Umeclidinium-d10 bromide
  • HY-A0030R

    mAChR Neurological Disease Metabolic Disease Cancer
    Fesoterodine (fumarate) (Standard) is the analytical standard of Fesoterodine (fumarate). This product is intended for research and analytical applications. Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB) .
    Fesoterodine (fumarate) (Standard)
  • HY-12100R

    mAChR Inflammation/Immunology Cancer
    Umeclidinium (bromide) (Standard) is the analytical standard of Umeclidinium (bromide). This product is intended for research and analytical applications. Umeclidinium bromide is a novel mAChR antagonist. The affinity (Ki) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.
    Umeclidinium (bromide) (Standard)
  • HY-B0406

    Carbamyl-β-methylcholine

    mAChR Neurological Disease Cancer
    Bethanechol (Carbamyl-β-methylcholine), a parasympathomimetic agent, is a mAChR agonist that exerts its effects via directly stimulating the mAChR (M1, M2, M3, M4, and M5) of the parasympathetic nervous system .
    Bethanechol
  • HY-B0406A
    Bethanechol chloride
    1 Publications Verification

    Carbamyl-β-methylcholine chloride

    mAChR Neurological Disease Cancer
    Bethanechol chloride (Carbamyl-β-methylcholine chloride), a parasympathomimetic agent, is a mAChR agonist that exerts its effects via directly stimulating the mAChR (M1, M2, M3, M4, and M5) of the parasympathetic nervous system .
    Bethanechol chloride
  • HY-122510

    Atropine oxidation

    Parasite Neurological Disease
    Atropine Oxide (Atropine oxidation), a derivative of Atropine, acts as a competitive antagonist to the muscarinic acetylcholine receptors M1, M2, M3, M4, and M5, and is utilized in the treatment of specific nerve agent and pesticide poisonings.
    Atropine oxide
  • HY-101281A

    mAChR Neurological Disease
    (Rac)-VU 6008667 is a selective negative allosteric modulator of muscarinic acetylcholine receptor subtype 5 (M5 NAM) (IC50=1.8 μM, pIC50= 5.75), has high CNS penetration .
    (Rac)-VU 6008667
  • HY-122510A

    Atropine oxidation hydrochloride

    mAChR
    Atropine Oxide (Atropine oxidation) hydrochloride, a derivative of Atropine, acts as a competitive antagonist to the muscarinic acetylcholine receptors M1, M2, M3, M4, and M5, and is utilized in the treatment of specific nerve agent and pesticide poisonings .
    Atropine oxide hydrochloride
  • HY-12567A

    (R)-VU0483253

    Drug Isomer Others
    (R)-ML375 ((R)-VU0483253) is an enantiomer of ML375 (HY-12567). (R)-ML375 is devoid of M5 mAChR activity (hM5, IC50>30 μM) .
    (R)-ML375
  • HY-127022A

    Endogenous Metabolite Neurological Disease
    Anisodine hydrobromide is a neuroprotective compound that interacts with muscarinic receptors (M1-M5) in cerebral ischemic diseases. Anisodine hydrobromide effectively reduces exacerbated M1, M2, M4, and M5 receptor expression in brain tissues under hypoxia/reoxygenation conditions. Anisodine hydrobromide demonstrates concentration-dependent inhibition of calcium ion influx and reactive oxygen species (ROS) levels, elucidating its neuroprotective mechanisms. Anisodine hydrobromide leads to decreased aspartate levels in HM cells during hypoxia, highlighting its effects on neurotransmitter modulation. Anisodine hydrobromide holds promising clinical prospects as a potential therapeutic agent for ischemic brain diseases, warranting further investigation into its mechanisms of action.
    Anisodine hydrobromide
  • HY-101839

    VU0488130

    mAChR Neurological Disease
    ML381 (VU0488130) is a highly selective, central nervous system penetrant mAChR M5 orthogonal antagonist (IC50 = 450 nM; Ki = 340 nM). ML381 is unstable in rat plasma and can be mainly used as a molecular probe for in vitro and electrophysiological studies .
    ML381
  • HY-B0406AS

    Carbamyl-β-methylcholine-d6 (chloride)

    mAChR Neurological Disease
    Bethanechol-d6 (chloride) is the deuterium labeled Bethanechol chloride. Bethanechol chloride (Carbamyl-β-methylcholine chloride), a parasympathomimetic agent, is a mAChR agonist that exerts its effects via directly stimulating the mAChR (M1, M2, M3, M4, and M5) of the parasympathetic nervous system[1].
    Bethanechol-d6 chloride
  • HY-107651
    VU 0365114
    1 Publications Verification

    mAChR Metabolic Disease
    VU 0365114 is a selective mAChR M5 positive allosteric modulator, with an EC50 of 2.7 μM, and >30 μM for M1, M2, M3 and M4 receptors. VU 0365114 increases insulin secretion stimulated by ACh in human β-cells .
    VU 0365114
  • HY-107646

    mAChR Neurological Disease
    PD 102807 is a M4 muscarinic receptor antagonist with an IC50 of 90.7 nM. PD 102807 inhibits M1, M2, M3, M5 muscarinic receptor with IC50s of 6558.7, 3440.7, 950.0, and 7411.7 nM, respectively . Antidyskinetic effect.
    PD 102807
  • HY-167849

    BBI-4000 tosylate

    mAChR Neurological Disease
    Sofpironium (BBI 4000) tosylate is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium tosylate reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium tosylate also has a high afnity for the M1, M2, M4 and M5 subtypes .
    Sofpironium tosylate
  • HY-19752A

    CID-25010775

    mAChR Neurological Disease
    VU0357017 hydrochloride (CID-25010775) is a potent, selective and brain-penetrant allosteric agonist of M1 muscarinic acetylcholine receptor, with an EC50 of 477 nM. VU0357017 hydrochloride is highly selective for M1 and has no activity at M2-M5 up to the highest concentrations tested (30 μM). VU0357017 hydrochloride can be used for the research of Alzheimer’s disease and schizophrenia .
    VU0357017 hydrochloride
  • HY-12158

    mAChR Neurological Disease
    VU0238441 is a pan muscarinic acetylcholine receptor (mAChR) positive allosteric modulator (PAM) with EC50s of 3.2 μM, 2.8 μM, 2.2 μM, 2.1 μM, >10 μM for M1, M2, M3, M5 and M4, respectively .
    VU0238441
  • HY-109013

    BBI 4000

    mAChR Neurological Disease
    Sofpironium bromide (BBI 4000) is an anticholinergic agent used in the study of primary axillary hyperhidrosis (PAH). Sofpironium bromide reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. Sofpironium bromide also has a high afnity for the M1, M2, M4 and M5 subtypes .
    Sofpironium bromide
  • HY-107656

    mAChR Neurological Disease
    PTAC oxalate is a selective muscarinic receptor ligand. PTAC oxalate is an partial agonist of M2 and M4 but antagonist of M1, M3, and M5 (Ki values of 0.2-2.8 nM for hM1-5 in CHO cells). PTAC oxalate alleviates the mechanical allodynia on the neuropathic pain and has antidepression effects .
    PTAC oxalate
  • HY-76570A

    (Rac)-Desfesoterodine hydrochloride; (Rac)-PNU-200577 hydrochloride

    mAChR Neurological Disease
    (Rac)-5-Hydroxymethyl Tolterodine ((Rac)-Desfesoterodine) hydrochloride, an active metabolite of Tolterodine, is a mAChR antagonist (Ki values of 2.3 nM, 2 nM, 2.5 nM, 2.8 nM, and 2.9 nM for M1, M2, M3, M4, and M5 receptors, respectively). (Rac)-5-Hydroxymethyl Tolterodine hydrochloride can be used for overactive bladder research .
    (Rac)-5-Hydroxymethyl Tolterodine hydrochloride
  • HY-76570

    (Rac)-Desfesoterodine; (Rac)-PNU-200577

    mAChR Neurological Disease
    (Rac)-5-Hydroxymethyl Tolterodine ((Rac)-Desfesoterodine), an active metabolite of Tolterodine, is a mAChR antagonist (Ki values of 2.3 nM, 2 nM, 2.5 nM, 2.8 nM, and 2.9 nM for M1, M2, M3, M4, and M5 receptors, respectively). (Rac)-5-Hydroxymethyl Tolterodine can be used for overactive bladder research .
    (Rac)-5-Hydroxymethyl Tolterodine
  • HY-A0030S

    mAChR Metabolic Disease
    Fesoterodine-d7 (fumarate) is the deuterium labeled Fesoterodine fumarate[1]. Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB)[2][3].
    Fesoterodine-d7 fumarate
  • HY-W002105R

    Endogenous Metabolite Others
    Fesoterodine (fumarate) (Standard) is the analytical standard of Fesoterodine (fumarate). This product is intended for research and analytical applications. Fesoterodine Fumarate is an orally active, nonsubtype selective, competitive muscarinic receptor (mAChR) antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. Fesoterodine Fumarate is used for the overactive bladder (OAB) .
    2,5-Furandicarboxylic acid (Standard)
  • HY-122203
    PCS1055 dihydrochloride
    2 Publications Verification

    mAChR Cholinesterase (ChE) Neurological Disease
    PCS1055 dihydrochloride is a potent, selective and competitive muscarinic M4 receptor antagonist with an IC50 of 18.1 nM and a Kd of 5.72 nM. PCS1055 dihydrochloride inhibits radioligand [ 3H]-NMS binding to the M4 receptor with a Ki of 6.5 nM. PCS1055 dihydrochloride exhibits >100-fold selectivity over M1-, M3-, and M5-receptors and 30-fold selectivity at the M2 receptor. PCS1055 dihydrochloride is also a potent AChE inhibitor with IC50 s of 22 nM and 120 nM for electric eel and human AChE, respectively .
    PCS1055 dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: